Savings from biosimilar medicines alone increased to $12.4 billion in 2023 and $36 billion since the first biosimilar entry in 2015, according to AAM's latest report.
Brimonidine Tartrate Ophthalmic Solution, 0.1%, is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.